Ophiomics

Ophiomics is a Portuguese precision medicine company focused on revolutionizing hepatology through AI-driven diagnostics. It leverages an integrated technology platform combining machine learning, multi-omics data, and in vitro diagnostics (IVD) to create tools for the full spectrum of liver disease management. As a clinical-stage, privately-held entity, it is developing its pipeline with an emphasis on responsible AI, clinical validation, and seamless integration into routine care to address significant unmet needs in liver health.

End-to-end integrated platform combining machine learning/AI, multi-omics data (genomics), and in vitro diagnostics (IVD) development. The platform encompasses data integration, reusable Dx-oriented omics technologies, and a unique R&D methodology for biomarker discovery focused on minimizing clinical and commercial risk.

The non-invasive liver diagnostics market is competitive, featuring established players with serum biomarker tests (e.g., FibroTest, ELF test) and imaging technologies (e.g., FibroScan), as well as numerous startups developing genomic, proteomic, and AI-driven solutions. Ophiomics differentiates through its integrated AI/omics platform and emphasis on responsible AI and full-spectrum disease management.